CRBP
Corbus Pharmaceuticals Holdings, Inc.
There isn't enough reported data to score CRBP yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CRBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CRBP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CRBP PE Valuation
CRBP has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CRBP Forward outlook
There aren't enough analyst estimates for CRBP to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CRBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.02 | -$0.49 |
| Q2 2026 | -$6.11 | -$1.33 |
| Q1 2026 | -$5.74 | -$1.50 |
| Q4 2025 | -$5.90 | -$2.22 |
| Q3 2025 | -$5.53 | -$0.90 |
| Q2 2025 | -$4.78 | +$0.97 |
| Q1 2025 | -$4.24 | +$2.66 |
| Q4 2024 | -$3.68 | +$6.63 |
CRBP is still losing money, but far less than before: $6.02 per share over the past year, against $53.40 at its worst in late 2020.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CRBP on earnings quality, reporting a profit while its opponent remains loss making.
CRBP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $97.3K | -92% |
| Q2 2021 | $136.6K | -52% |
| Q1 2021 | $647.8K | -63% |
| Q4 2020 | $658.2K | -74% |
UNH has the stronger quarterly revenue trend. Revenue is down 100% for CRBP versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2021 | -14257% | -11496 points |
| Q2 2021 | -12230% | +1089 points |
| Q1 2021 | -2379% | -683 points |
| Q4 2020 | -3162% | -2105 points |
| Q3 2020 | -2761% | N/A |
| Q2 2020 | -13319% | N/A |
| Q1 2020 | -1696% | N/A |
| Q4 2019 | -1057% | N/A |
CRBP's operating margin was −14257% last quarter, down 11496 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
CRBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$21.3M | -$5.7M |
| Q2 2026 | -$29.6M | -$13M |
| Q1 2026 | -$25.6M | -$9.2M |
| Q3 2025 | -$15.6M | -$1.6M |
| Q2 2025 | -$16.6M | -$7.7M |
| Q1 2025 | -$16.4M | -$8.5M |
| Q4 2024 | -$10.9M | -$4.9M |
| Q3 2024 | -$13.9M | -$6.8M |
UNH has the stronger cash trend. Its trailing FCF is up 5.2% versus its history, compared with CRBP at down 64%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
CRBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +1.4M shares |
| 1 year | +70% | +8.6M shares |
| 3 years | +398% | +16.7M shares |
| 5 years | +437% | +17M shares |
| Available history | +878% | +18.7M shares |
CRBP has 21M diluted shares, up 70% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CRBP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CRBP Net Leverage
CRBP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CRBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 4.8 | Oversold |
CRBP's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CRBP PE vs Healthcare Sector
CRBP has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CRBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.74 | 28% below |
| 20 week MA | $7.61 | 55% below |
| 50 week MA | $8.42 | 60% below |
| 100 week MA | $9.05 | 62% below |
| 200 week MA | $14.9 | 77% below |
CRBP is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CRBP on trend strength, trading above more of its moving averages.
CRBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $162.3 | $41.7 | -74% |
| 2021 | $41.7 | $21.0 | -50% |
| 2022 | $21.0 | $3.57 | -83% |
| 2023 | $3.57 | $6.04 | +69% |
| 2024 | $6.04 | $12.8 | +111% |
| 2025 | $12.8 | $8.33 | -35% |
| 2026 YTD | $8.33 | $3.41 | -59% |
CRBP's yearly returns have swung widely, from +111% in 2024 to −83% in 2022. It's down 59% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CRBP on returns for 2026, with the stronger performance.